San Francisco, CA, January 07, 2019--(PRWirePro.com)-- Gamida Cell Ltd. (Nasdaq:GMDA), a leading cellular and immune therapeutics company, reported expected milestones for 2019, which highlight the company's progress advancing its clinical development candidates: NiCord®, an investigational universal bone marrow donor source in late-stage development for patients with hematologic malignancies (blood cancers), and NAM-NK, an investigational, cell-based cancer immunotherapy in development in patients with non-Hodgkin lymphoma and multiple myeloma.
VIEW FULL PRESS RELEASE
Press Release DistributionDistributed to 1000+ NetworksInclusion on MarketWatch & Business Journals, ABC, NBC, CBS and FOX affiliates, Local, National, DowJones Factiva Network, Comtex News Network, Digital Journal and moreIncludes PRWeb, Cision and PRNewswire DistributionNever Expires (Submit anytime)Access to 24/7 Editorial Staff & PR ResourcesIncludes 45,000 Targeted press release impressions through Google AdRelease ™
Visit https://prwirepro.com to learn more
Comments
Post a Comment